Clinical observation of Endostar combined with TP chemotherapy in the treatment of advanced stage NSCLC

Chinese Journal of Clinical Oncology

Volumn 36, Issue 21, 2009, Pages 1205-1207

  Han, Lichun ^a   Xing, Dejun ^a  

^a Tumor Hospital of Jilin Province   (China)

Author keywords

Chemotherapy; Endostar; Non small cell lung cancer

Indexed keywords

CISPLATIN; DOCETAXEL; ENDOSTAR; ENDOSTATIN; UNCLASSIFIED DRUG;

ADVANCED CANCER; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOLOGY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; GASTROINTESTINAL DISEASE; HAIR LOSS; HISTOPATHOLOGY; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE;

EID: 73949134628     PISSN: 16727118     EISSN: None     Source Type: Journal    
DOI: 10.3969/j.issn.1000-8179.2009.21.002     Document Type: Article

References (8)

1. Laskin JJ, Sandler AB. First-line treatment for advanced non-small cell lung cancer [J]. Oncology (Williston Park), 2005, 19(13): 1671-1680.
2. Chinese source
3. Chinese source
4. Chinese source
5. Itasaka S, KomakiR, HerbstRS, et al. Endostatin improves radio - response and blocks tumor revascularization after radiation therapy forA431 xenografts in mice[J]. Int J RadiatOncol Biol Phys,2007, 67(3): 870-878.
6. Chinese source
7. Chinese source
8. Chinese source